Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Once-weekly exenatide NDA review for type 2 diabetes extended by FDA

Feb. 26, 2010

GSK criticizes Senate Committee on Finance's report on Avandia

Feb. 25, 2010

Shire receives FDA fast track designation for Replagal

Feb. 25, 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA for filing

Feb. 25, 2010

Amylin and Takeda to begin phase III trial of pramlintide/metreleptin in obesity

Feb. 23, 2010

Takeda and Affymax begin phase III trial of Hematide in chronic renal failure

Feb. 23, 2010

GSK and FDA present safety update on Avandia for type 2 diabetes

Feb. 23, 2010

BioSante reports phase III LibiGel safety data

Feb. 23, 2010

PPARdelta agonists discovered at sanofi-aventis

Feb. 23, 2010

EnzymeRx provides clinical update on pegsitacase

Feb. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...